Title : A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial.

Pub. Date : 2021 Feb 23

PMID : 33591324






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Rituximab plus cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) is the standard of care for untreated diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide DNA damage inducible transcript 3 Homo sapiens